BIOMAT Database Logo BIOMAT Database Logo

Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. 2007

Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Center for Structural Biology and Department of Biochemistry, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA.

Human fatty acid synthase (FAS) is uniquely expressed at high levels in many tumor types. Pharmacological inhibition of FAS therefore represents an important therapeutic opportunity. The drug Orlistat, which has been approved by the US Food and Drug Administration, inhibits FAS, induces tumor cell-specific apoptosis and inhibits the growth of prostate tumor xenografts. We determined the 2.3-A-resolution crystal structure of the thioesterase domain of FAS inhibited by Orlistat. Orlistat was captured in the active sites of two thioesterase molecules as a stable acyl-enzyme intermediate and as the hydrolyzed product. The details of these interactions reveal the molecular basis for inhibition and suggest a mechanism for acyl-chain length discrimination during the FAS catalytic cycle. Our findings provide a foundation for the development of new cancer drugs that target FAS.

UI MeSH Term Description Entries
D007783 Lactones Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES. Lactone
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000077403 Orlistat A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity. 1-((3-Hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate,Alli,Ro-18-0647,THLP,Tetrahydrolipastatin,Tetrahydrolipstatin,Xenical,Ro 18 0647
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D017434 Protein Structure, Tertiary The level of protein structure in which combinations of secondary protein structures (ALPHA HELICES; BETA SHEETS; loop regions, and AMINO ACID MOTIFS) pack together to form folded shapes. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Tertiary Protein Structure,Protein Structures, Tertiary,Tertiary Protein Structures

Related Publications

Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase.
October 2014, ACS catalysis,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain.
November 2004, Proceedings of the National Academy of Sciences of the United States of America,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Novel antagonists of the thioesterase domain of human fatty acid synthase.
July 2007, Molecular cancer therapeutics,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Computational screening of fatty acid synthase inhibitors against thioesterase domain.
November 2018, Journal of biomolecular structure & dynamics,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
January 2015, Journal of medicinal chemistry,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Complete amino acid sequence of the thioesterase domain of chicken liver fatty acid synthase.
October 1988, Biochemistry,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Crystal structure of FAS thioesterase domain with polyunsaturated fatty acyl adduct and inhibition by dihomo-gamma-linolenic acid.
September 2011, Proceedings of the National Academy of Sciences of the United States of America,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Primary structure of a chymotryptic peptide containing the "active serine" of the thioesterase domain of fatty acid synthase.
November 1981, Biochemical and biophysical research communications,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands.
March 2008, Proteins,
Charles W Pemble, and Lynnette C Johnson, and Steven J Kridel, and W Todd Lowther
The crystal structure of a mammalian fatty acid synthase.
September 2008, Science (New York, N.Y.),
Copied contents to your clipboard!